Global Medicare · Endometrial Research

RegenEndo

Study 03-REGEN-AR

A prospective observational study comparing endometrial development and reproductive parameters associated with two autologous PRP preparation approaches used within routine clinical care at IVF Baden-Baden.

Prospective Observational IVF Baden-Baden

Participation in the study is separate from clinical care. Treatment selection and final research eligibility remain with the authorised medical and research teams.

Study overview

RegenEndo at a glance.

03-REGEN-AR is the endometrial observational study conducted at IVF Baden-Baden under the direction of Prof. Dr. med. Wolfgang Küpker.

0 planned participants
52 / 52 Standard-PRP / IAS
20–50 years · general study population
Endometrial
thickness
primary comparison parameter

Primary research question

?

Does endometrial development differ between patients receiving Standard-PRP and IAS within routine clinical care?

The principal comparison focuses on endometrial development, particularly endometrial thickness, after the two autologous preparation approaches.

Study participation does not determine which preparation is used. That decision belongs to clinical care.

Study design

Designed to observe routine endometrial clinical care.

RegenEndo prospectively documents defined endometrial and reproductive parameters in patients receiving Standard-PRP or IAS as part of routine clinical care.

01 Prospective

Study information is documented forward in time.

02 Observational

The study observes clinical care rather than assigning treatment.

03 Single-centre

The study is conducted at IVF Baden-Baden.

04 Non-randomised

Standard-PRP and IAS are not randomly allocated by the study.

Study population

A diverse endometrial and implantation-related population.

The general study population includes women aged 20 to 50 years with endometrial or implantation-related clinical profiles relevant to the protocol.

These are general population profiles. They do not constitute an online eligibility checklist.

01 Asherman syndrome Intrauterine adhesions and thin endometrium after adhesiolysis are represented within the research population.
02 Atrophic / refractory endometrium Persistently thin endometrium without another identified cause forms another clinical profile.
03 Treated chronic endometritis Previous chronic endometritis associated with implantation concerns may form part of the clinical history.
04 Adenomyosis Adenomyosis is another uterine and endometrial-related profile represented in the protocol.
05 Repeated implantation failure Repeated unsuccessful implantation is included within the study population.
06 Recurrent pregnancy loss Recurrent pregnancy loss without another identified explanation also forms part of the research framework.

Observation pathway

From clinical assessment to prospective endometrial observation.

The study follows predefined endometrial parameters within the routine clinical pathway while keeping treatment decisions independent from research participation.

01 · BASELINE Clinical context

Relevant endometrial and reproductive information is documented.

02 · CLINICAL CARE Standard-PRP or IAS

The preparation approach is selected independently by the clinical team.

03 · OBSERVATION Endometrial development

Defined ultrasound and endometrial parameters are documented prospectively.

04 · WHEN APPLICABLE Reproductive follow-up

Implantation and reproductive outcomes can be documented where applicable.

Study parameters

Endometrial development is observed in multiple dimensions.

Thickness is the primary comparison parameter, accompanied by additional morphological, volumetric, vascular and reproductive information.

PRIMARY Thickness

Endometrial thickness is the central primary comparison parameter.

3D Volume & pattern

Three-dimensional and morphological information forms part of the broader assessment.

POWER DOPPLER VI · FI · VFI

Endometrial and subendometrial vascularisation indices are documented.

CLINICAL Reproductive outcomes

Implantation, pregnancy and other reproductive outcomes may be documented when applicable.

These are study parameters. This website does not use individual measurements to predict implantation, pregnancy or treatment success.

Autologous preparations

Two clinical preparation approaches. One observational comparison.

Standard-PRP and IAS are both autologous preparations derived from the patient’s own blood.

IAS includes additional processing of naturally occurring components from fractions of the same autologous sample.

The clinical preparation is selected before and independently of research participation.

RegenEndo does not establish that IAS is clinically superior to Standard-PRP. IAS should not be described as purified exosome therapy.

Research governance

Conducted at IVF Baden-Baden.

RegenEndo is conducted under the direction of Prof. Dr. med. Wolfgang Küpker.

Study centre IVF Baden-Baden · Germany
Principal Investigator Prof. Dr. med. Wolfgang Küpker
Study 03-REGEN-AR · RegenEndo
Data handling Study information is handled in pseudonymised form.
Clinical decision Remains independent from research participation.

Important research information

Research information should not be confused with clinical eligibility.

Does this page confirm whether I am eligible for RegenEndo?
No. The page describes general study characteristics. Final eligibility can only be assessed by the authorised medical and research teams after reviewing the full protocol criteria.
Does RegenEndo decide whether I receive Standard-PRP or IAS?
No. The preparation approach is selected within routine clinical care independently from participation in 03-REGEN-AR.
Does a specific endometrial thickness automatically determine eligibility?
No. Individual ultrasound measurements require clinical interpretation and do not replace the complete protocol criteria or specialist assessment.
Does participation guarantee greater endometrial thickness or pregnancy?
No. Participation does not guarantee increased endometrial thickness, implantation, pregnancy, live birth or another individual health benefit.
Can I enrol directly through Global Medicare?
Global Medicare provides information and initial coordination. Direct inclusion in the study is not confirmed online; any possible research participation is assessed separately by the authorised clinical and research teams.

Your next step

Interested in discussing your endometrial situation?

The Endometrial Program is the patient pathway for initial orientation, specialist assessment and coordination. Research participation, when applicable, is considered separately by the authorised medical and research teams.

/* JS para menú plegable móvil Divi */